Business
Archived — This article has been archived. The information may be outdated.
Escalating duties target India's US generic dominance
NDTV··23 Jul
Indian pharma firms built scale supplying affordable generics across American pharmacies. A staged tariff ladder gives brief relief before punitive rates aim to reshore production. Exporters may reroute volumes or absorb costs, but margins on low-price molecules are thin. Washington's timeline leaves limited room to renegotiate before August implementation. Trump's generic drug tariffs start August 1, 2026 at zero for.
Prism
What It Means For You
- India exports about $9.7 billion in pharma to the United States, roughly 38 percent of global generic shipments.
- Tariffs starting August 1 rise from 0 percent for two years to 100 percent in year three.
- Rates could reach 200 percent afterward under Trump's generic drug tariff framework.
What's Happening
- Trump announced escalating generic drug tariffs effective August 1, 2026.
- The plan starts at zero for two years, then jumps to 100 percent in year three.
- India's US-bound pharma exports make it among the most exposed suppliers.
Pharma Exports Face Escalating Duties
- Indian generic makers supply a large share of US prescription volumes.
- Escalating duties aim to reshore pharmaceutical manufacturing to America.
- Industry groups will lobby for exemptions before the August start date.
all-newstop-stories
